Paloma Martin-Martorell - JoVE Visualize

Search research articles

Contact Us

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Privacy Policy

Policies

Search research articles

Contact Us

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Privacy Policy

Policies

Filters

Paloma Martin-Martorell

Showing results (1-10 of 2) with videos related to

Pageof 1

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant TrialAditya Bardia, Marina Parton, Sherko Kümmel, et al.

BMC Cancer|July 22, 2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.

Pageof 1

Search research articles

Showing results (1-10 of 2) with videos related to

Sort By:

Pageof 1

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant TrialAditya Bardia, Marina Parton, Sherko Kümmel, et al.

BMC Cancer|July 22, 2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.

Pageof 1